Cholesterol-Lowering Drugs and Incident Open-Angle Glaucoma: A Population-Based Cohort Study

Abstract

BackgroundOpen-angle glaucoma (OAG) is a progressive neurodegenerative disease that may lead to blindness. An elevated intraocular pressure (IOP) is its major risk factor. OAG treatment is currently exclusively directed towards the lowering of the IOP. IOP lowering does not prevent disease progression in all patients and thus other treatment modalities are needed. Earlier studies reported cholesterol-lowering drugs to have neuroprotective properties. The aim of this study was to determine the associations between the use of cholesterol-lowering drugs and incident OAG.Methodology/Principal FindingsParticipants in a prospective population-based cohort study underwent ophthalmic examinations, including IOP measurements and perimetry, at baseline and follow-up. The use of statins and non-statin cholesterol-lowering drugs was monitored continuously during the study. Associations between the use of cholesterol-lowering drugs and incident OAG were analyzed with Cox regression; associations between cholesterol-lowering drugs and IOP at follow-up were analyzed with multiple linear regression. During a mean follow-up of 9.8 years, 108 of 3939 eligible participants (2.7%) developed OAG. The hazard ratio for statin use was 0.54 (95% confidence interval 0.31–0.96; P = 0.034) and for non-statin cholesterol-lowering drugs 2.07 (0.81–5.33; P = 0.13). The effect of statins was more pronounced with prolonged use (hazard ratio 0.89 [0.41–1.94; P = 0.77] for use two years or less; 0.46 [0.23–0.94; P = 0.033] for use more than two years; P-value for trend 0.10). The analyzes were adjusted for age and gender, baseline IOP and IOP-lowering treatment, the family history of glaucoma, and myopia. There was no effect of statins on the IOP.Conclusions/SignificanceLong-term use of statins appears to be associated with a reduced risk of OAG. The observed effect was independent of the IOP. These findings are in line with the idea that statins have neuroprotective properties and may open a way to a new OAG treatment modality.

Radiation treatment inhibits monocyte entry into the optic nerve head and prevents neuronal damage in a mouse model of glaucoma

“…Statins are also known to reduce transendothelial migration. Interestingly, some studies have shown that long-term statin use appears to be associated with a reduced risk of open-angle glaucoma (78,79). However, given both the robust and long-term efficacy of a single dose of xray radiation in preventing cellular entry into the optic nerve and retina, it will be important to further evaluate the use of x-rays for preventing glaucoma and other inflammatory conditions.…”

Glaucoma and ocular blood flow: an anatomical perspective

“…If lifestyle changes prove to be beneficial in modifying glaucoma risk in a safe manner, they can prove difficult to incorporate into one's life. New medications such as statins, which not only improve a vascular profile in general but also have neuroprotective properties and improve endothelial cell dysfunction, may be used in the future for the treatment of glaucoma after more is understood about this disease process [44,131].…”

Continuous Intraocular Pressure Monitoring During Nocturnal Sleep in Patients With Obstructive Sleep Apnea Syndrome

“…24 Most of these abnormalities are related to the elevation of intraocular pressure (IOP) causing damage to the optic nerve head directly. 25 However, given that at least some glaucoma patients have a normal or relatively low IOP range, other systemic conditions, such as diabetes, cardiovascular disease, and obesity, may also be relevant. 26,27 Numerous previous studies have described the involvement of primary open-angle glaucoma and normal-tension glaucoma in patients with OSAS.…”